Open Orphan has successfully raised capital in an oversubscribed fundraise
Open Orphan Plc has completed an equity placing to raise US$15.5 million to maximize available COVID-19 opportunities and testing.
Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Open Orphan comprises of two commercial specialist CRO services businesses: hVIVO and Venn Life Sciences, and has offices in London, Dublin, Paris and the Netherlands. The company is led by a management team with deep industry and financial experience.
Oaklins Cavendish’s sister firm finnCap, based in the UK, advised Open Orphan Plc on its oversubscribed equity fundraising of US$15.5 million.
Talk to the deal team
Related deals
Winking Studios Limited completes a secondary fundraising of US$20 million
Winking Studios has successfully raised US$20 million to fund its business strategy and future plans, such as strategic acquisitions, alliances and joint ventures as well as secondary or dual listings, to grow the group’s market share and broaden its customer base globally.
Learn moreFRP Advisory Group plc has finalized a successful secondary placing
FRP Advisory Group plc has completed a fundraising. The book was oversubscribed and approximately £20.4 million (US$33 million) of shares were sold by certain directors and partners of FRP to new and existing institutional investors at 128 pence per ordinary share.
Learn moreLeika Medical Equipments Ltd. has been acquired by Angus Capital
The shareholders of Leika Medical Equipments Ltd. have sold the company to Angus Capital.
Learn more